首页> 外文期刊>American Journal of Cancer Prevention >The Survival of Nodal Non-Hodgkin’s Lymphoma Patients in the West of Iran
【24h】

The Survival of Nodal Non-Hodgkin’s Lymphoma Patients in the West of Iran

机译:伊朗西部淋巴结非霍奇金淋巴瘤患者的生存

获取原文
           

摘要

Background: Most non-Hodgkin’s lymphomas (NHL) arise in lymph nodes or other lymphatic tissues such as the spleen, Waldeyer’s ring and thymus. The aim of study is to evaluate the survival in nodal NHL patients for the first time in the west of Iran. Patients and Methods: Fifty-three patients with nodal NHL referred to Our Clinic from 2002-2014. We checked age, sex, histopathology reports, anatomic sites and survival for them. One representative Material of patients with diffuse large B-cell lymphoma (DLBL), FL, SLL and anaplastic lymphoma was re-classified after revision. The overall survival (OS) was plotted by GraphPad Prism 5 software. Results: For all patients, the median age at diagnosis was 52±16.92 (range, 16-92 years) that 26 patients (49.1%) had age≤50 years. Thirty-four patients (64.2%) were male. Involvement anatomic sites were axillary, neck, inguinal, cervical, mediasten, bone marrow, abdominal, bladder, tonsil and supraclavicular for 11 patients (20.6%), 9(17%), 9(17%), 8(15.2%), 6(11.3%), 5(9.4%), 2(3.8%), 1(1.9%), 1(1.9%) and 1(1.9%), respectively. The 3-year, 5-year and 10-year survival rates are 65%, 54.2% and 51%, respectively. Conclusion: The OS in this study is higher than a number of studies and the median age is lower. Also, the male-to-female ratio for nodal lymphoma is higher than other studies and nodal NHL patients accrue more in males.
机译:背景:大多数非霍奇金淋巴瘤(NHL)发生在淋巴结或其他淋巴组织,例如脾脏,Waldeyer环和胸腺。研究的目的是首次评估伊朗西部淋巴结非霍奇金淋巴瘤患者的生存率。患者与方法:2002年至2014年,共有53例结节性NHL患者转诊至我们的诊所。我们检查了他们的年龄,性别,组织病理学报告,解剖部位和生存率。修订后将弥散性大B细胞淋巴瘤(DLBL),FL,SLL和间变性淋巴瘤的一种代表性材料进行了重新分类。通过GraphPad Prism 5软件绘制总生存期(OS)。结果:所有患者的诊断中位年龄为52±16.92(范围16-92岁),其中26位患者(49.1%)的年龄≤50岁。三十四名患者(64.2%)是男性。 11例患者(20.6%),9(17%),9(17%),8(15.2%)的受累解剖部位为腋窝,颈部,腹股沟,宫颈,中间,骨髓,腹部,膀胱,扁桃体和锁骨上分别为6(11.3%),5(9.4%),2(3.8%),1(1.9%),1(1.9%)和1(1.9%)。 3年,5年和10年生存率分别为65%,54.2%和51%。结论:本研究中的OS高于许多研究,中位年龄较低。此外,淋巴瘤的男女比例高于其他研究,淋巴结非霍奇金淋巴瘤患者的男性发病率更高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号